ट्रेसविस्टाने 2020 मध्ये साथीचा रोग असूनही उत्कृष्ट कामगिरीबद्दल विश्लेषक आणि सहयोगी यांना 50,000 रुपये बोनस एक रकमी देण्याची घोषणा केली

- 

ट्रेसविस्टाने 2020 मध्ये साथीचा रोग असूनही उत्कृष्ट कामगिरीबद्दल विश्लेषक आणि सहयोगी यांना 50,000 रुपये बोनस एक रकमी देण्याची घोषणा केली
मुंबई 22 फेब्रुवारी 2021:- कॉर्पोरेट्स, मालमत्ता व्यवस्थापक आणि उद्योजकांना हाय-एंड आउटसोर्स पाठिंबा देणारा अग्रगण्य प्रदाता असलेल्या ट्रेसव्हीस्टाने थकबाकीबद्दल आभार व्यक्त करण्यासाठी प्रत्येक विश्लेषक आणि सहयोगी (समकक्ष) साठी प्रत्येक रिव्हिव चक्रात (across review cycles) 50,000 रुपये वन-टाइम बोनस देण्याचे जाहीर केले आहे. 2020 (साथीचा रोग) सर्व देशभर असूनही त्यांची कामगिरी उत्तम झाली होती. ट्रेसविस्टा जुलै 2021 पर्यंत संपूर्ण वेतन पुनिरीक्षण अभ्यासक्रम हाती घेईल आणि प्रशिक्षण व तंत्रज्ञानात मोठ्या प्रमाणात गुंतवणूक करण्याची योजना ते आखत आहे. सध्याच्या सीएजीआर 30% मध्ये ट्रेसविस्टाला चार वर्षांत 2,500 लोकांची संख्या असण्याची अपेक्षा आहे.
संचालक व सह-संस्थापक सुदीप मिश्रा यांनी या घोषणेवर भाष्य केले की, “ट्रेसविस्टा नेहमीच एक कर्मचारी-केंद्रित संस्था राहिली आहे आणि आम्ही सतत अधिक चांगले करण्याचा प्रयत्न करतो. बोनस हा एक आमच्या कर्मचार्‍यांचे आभार मानण्याचे मार्ग आहे ज्यांनी काम करून घेतले आहे. साथीच्या आजारामुळे उद्भवणारी आव्हानात्मक परिस्थिती. आमचे उद्दीष्ट ट्रेसविस्टाच्या प्रभावापर्यंतचे व्यापक आणि सखोल असावे आणि उत्कृष्टतेशी निगडित रहावे."

Comments

Post a Comment

Popular posts from this blog

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

-
  Indegene acquires Trilogy Writing & Consulting GmbH,  a medical writing consultancy   India, March 27, 2024:  Indegene, a  digital-first, life sciences commercialization company , announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.   Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output. Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutica
Read more

TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India

-
Image
TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India Mumbai, 09 June 2023 : The 16th Edition of TiEcon Mumbai, organised by TiE Mumbai at Jio Convention Centre, BKC culminated on an enthusiastic note with a call to build an Anti-Fragile and Sustainable India. It kick-started with marquee speakers focusing on ways to accelerate growth, drive more intelligent engagement, make conscious choices and methods to empower sustainable business building ideas. Speaking at the summit, Ranu Vohra, President- TiE Mumbai said, “It was great to see the energy of the startup eco system at work at TiECon 2023. There were lively debates on Mumbai’s roadmap to becoming the startup hub, Gen AI and its role in India and the opportunities, thus created. The session on funding availability held out promise that as the startups become “anti-fragile” and focus on unit economics and profitability we should see a renewed incre
Read more

REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24

-
REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24   REC RECORDS ITS HIGHEST EVER QUARTERLY PROFIT AT ₹3,773 CRORE Mumbai/New Delhi, November 01, 2023: REC limited, a ‘Maharatna’ company under the administrative control of the Ministry of Power, Government of India, and registered with RBI as Non-Banking Finance Company (NBFC), Public Financial Institution (PFI) and Infrastructure Financing Company (IFC), has today reported its unaudited financial results (Standalone) for the 2nd Quarter and Half Year ended 30th September 2023. Key highlights are as under:  Operational and Financial Highlights –Q2 FY24 vs Q2 FY23 (Standalone) • Sanctions: ₹ 1,04,366 crore vs. ₹ 84,889 crore, up 23%, Renewable sector constitutes for 24% • Disbursements: ₹ 41,598 crore vs. ₹ 17,827 crore, up 133% • Interest Income on Loan Assets: ₹ 11,213 crore vs. ₹ 9,534 crore, up 18% • Net Profit: ₹ 3,773 crore vs. ₹ 2,728 crore, up 38% • Total Comprehensive Income: ₹ 4,188 crore vs. ₹ 1,915 crore, up 1
Read more